Madison Avenue Partners, LP: THERAVANCE BIOPHARMA INC (TBPH): Quarterly 13F Position History
As of Q1 2026, Madison Avenue Partners, LP reported 9,511,150 shares of THERAVANCE BIOPHARMA INC (TBPH), worth $154.4M and representing 6.7% of its 13F equity book. The position first appeared in Q3 2021 and has been disclosed across 19 13F-HR filings in Pactolio's tracked window.
- 9,511,150Shares Held (Latest Filing)
- $154.4MReported Market Value (Latest Filing)
- 6.7%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$23.6MQuarter-over-Quarter Value Change
- 9,511,150Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 19 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 9,511,150 | 0 | — | $154.4M | 6.7% | $16.2 |
| Q4 2025 | 9,511,150 | 0 | — | $178.0M | 7.6% | $18.7 |
| Q3 2025 | 9,511,150 | 0 | — | $138.9M | 8.3% | $14.6 |
| Q2 2025 | 9,511,150 | 0 | — | $104.9M | 7.0% | $11.0 |
| Q1 2025 | 9,511,150 | 0 | — | $84.9M | 7.2% | $8.9 |
| Q4 2024 | 9,511,150 | 0 | — | $89.5M | 9.5% | $9.4 |
| Q3 2024 | 9,511,150 | +999,800 | +11.7% | $76.7M | 7.1% | $8.1 |
| Q2 2024 | 8,511,350 | +1,499,124 | +21.4% | $72.2M | 9.1% | $8.5 |
| Q1 2024 | 7,012,226 | 0 | — | $62.9M | 10.1% | $9.0 |
| Q4 2023 | 7,012,226 | 0 | — | $78.8M | 11.1% | $11.2 |
| Q3 2023 | 7,012,226 | 0 | — | $60.5M | 8.6% | $8.6 |
| Q2 2023 | 7,012,226 | 0 | — | $72.6M | 15.8% | $10.3 |
| Q1 2023 | 7,012,226 | 0 | — | $76.1M | 16.4% | $10.8 |
| Q4 2022 | 7,012,226 | 0 | — | $78.7M | 13.9% | $11.2 |
| Q3 2022 | 7,012,226 | 257,358 | -3.5% | $71.1M | 15.3% | $10.1 |
| Q2 2022 | 7,269,584 | 0 | — | $65.9M | 13.5% | $9.1 |
| Q1 2022 | 7,269,584 | +621,559 | +9.3% | $69.5M | 13.0% | $9.6 |
| Q4 2021 | 6,648,025 | +1,718,602 | +34.9% | $73.5M | 15.9% | $11.1 |
| Q3 2021 | 4,929,423 | — | — | $36.5M | 8.1% | $7.4 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Madison Avenue Partners, LP first disclose a TBPH position in 13F-HR filings?
Madison Avenue Partners, LP first reported THERAVANCE BIOPHARMA INC (TBPH) on its 13F-HR filing for the period ending 2021-09-30 (Q3 2021). The position has appeared on 19 reported quarters within Pactolio's tracked window.
What was Madison Avenue Partners, LP's most recent quarter-over-quarter share-count change in TBPH?
Madison Avenue Partners, LP held the same 9,511,150 shares of TBPH between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Madison Avenue Partners, LP's cost basis in TBPH?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.